Prospective Cohort Study in Patients With NAFLD
Recruiting · NCT00575133 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Zurich
View the official record on ClinicalTrials.gov →What this trial is about
To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)will be analyzed prospectively from a liver tissue bank.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with histologically confirmed fatty liver disease
Exclusion criteria
- History of significant alcohol consumption
- Viral hepatitis
- Autoimmune hepatitis
- Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)
- Hepatotoxic medication (e.g. amiodarone).
Where it is running
1 location listed.
- University Hospital Zurich, Endocrinology and Diabetology - Zurich, Canton of Zurich, Switzerland